By M. Marin
READ THE FULL QNRX RESEARCH REPORT
Among broadest development pipelines focused on rare dermatologic diseases, with three core markets identified – U.S., EU, Japan – & partnership sales network for ROW
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical stage, specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, provided a business update earlier this month. As the company advances lead asset QRX003 and pipeline assets, QNRX has made strong advances in recent months. For example, Quoin recently received FDA conditional approval for the proposed brand name for QRX003 for Netherton Syndrome (NS): QYLEKI™. QNRX is most advanced in studying QRX003 for NS, but it is also studying this asset for Peeling Skin Syndrome (PSS), per its strategy to design assets to treat multiple indications and potentially broaden their commercial prospects and scalability.
QNRX’s Ichthyosis focused platform is most advanced regarding NS, as noted, but the company also continues to advance QRX003 into additional rare dermatologic indications. In addition to treatment of NS, QRX003 is also being evaluated for pediatric NS and PSS. Quoin recently received FDA IND clearance to initiate a Phase 2 study of QRX003 in PSS. Separately, QNRX also announced a positive clinical update from its ongoing pediatric NS Compassionate Use program. QNRX has indicated that the recent FDA clearance for PSS represents the first-ever clearance for formal clinical study for a potential PSS therapy. Concurrently, QRX009, QNRX’s topical rapamycin platform, remains on track to launch clinical activities in multiple indications that have limited or no other approved treatments.
Quoin has identified three core markets – the U.S., E.U, and Japan – for QRX003 and potentially other assets once/if they are commercialized. With both QRX003 and QRX009 advancing, the company believes it is developing one of the broadest development pipelines focused on rare dermatologic diseases. Assessing assets for multiple indications can help spread costs over an expanded base.
The company has made significant progress towards launching in these core markets. For example, Quoin has established a Japanese subsidiary to commercialize QRX003 in that key market, where Japan’s regulatory authority, MHLW, granted Orphan Drug Designation (ODD) for QRX003 in NS. Japan’s ODD designation is expected to provide benefits such as R&D subsidies, tax credits for qualified clinical testing, reduction of MHLW application fees, priority review, and ten years of market exclusivity, if QRX003 is approved. In addition, the company has multiple regulatory designations for QRX003 in place and/or under review in these and other regions.
As QNRX continues to expand IP protection portfolio, U.S. Notice of Allowance for a patent covering combination treatment for NS received
In terms of protecting its assets and IP, QNRX received a U.S. Notice of Allowance for a patent covering combination treatment for NS (U.S. Patent Application No. 18/428,570, titled Combination Treatment for Netherton Syndrome). The company continues to file multiple patent applications to protect its assets and IP. The company has filed numerous patent applications to protect its IP. Recently, QNRX filed patents for novel topical rapamycin formulations. Quoin has filed U.S. and international patent applications for novel topical rapamycin formulations targeting microcystic lymphatic malformations, venous malformations and angiofibromas. The products are being developed using Quoin’s in-licensed proprietary Invisicare® delivery technology. The company believes this represents an important measure in expanding its pipeline addressing rare dermatological diseases.
QNRX believes it is on track to initiate its Phase 3 NS trial by year-end 2026 and potentially file a New Drug Application (NDA) in 2027 for QRX003 as the first approved treatment for NS. At its Type C meeting with the FDA for QRX003 in NS in March 2026, the FDA indicated that a single Phase 3 study might be sufficient to support regulatory approval.
Quoin is currently conducting two pivotal clinical studies for QRX003 in NS that have generated positive data thus far. Specifically, clinical data to date have demonstrated clear evidence of rapid, prolonged, and almost complete skin healing following twice-daily application of QRX003 to the treatment areas, along with the almost complete elimination of key symptoms such as chronic, debilitating pruritus, and have facilitated zero nightly sleep disturbances.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
